The European Commission has announced the adoption of two reasoned opinions calling the end of the export restriction systems implemented in Portugal and Slovakia.
The EC is urging Portugal and Slovakia to remove unjustified and disproportionate notification requirements related to the export of medicinal products for human use to other European Union member states.
The Commission believes that the rules in these member states create obstacles to the free movement of goods within the European Union single market (Articles 34–36 of TFEU). Parallel trade in medicines refers to instances where medicinal products are purchased in one member state and then sold in other member states.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze